<code id='645C598F7E'></code><style id='645C598F7E'></style>
    • <acronym id='645C598F7E'></acronym>
      <center id='645C598F7E'><center id='645C598F7E'><tfoot id='645C598F7E'></tfoot></center><abbr id='645C598F7E'><dir id='645C598F7E'><tfoot id='645C598F7E'></tfoot><noframes id='645C598F7E'>

    • <optgroup id='645C598F7E'><strike id='645C598F7E'><sup id='645C598F7E'></sup></strike><code id='645C598F7E'></code></optgroup>
        1. <b id='645C598F7E'><label id='645C598F7E'><select id='645C598F7E'><dt id='645C598F7E'><span id='645C598F7E'></span></dt></select></label></b><u id='645C598F7E'></u>
          <i id='645C598F7E'><strike id='645C598F7E'><tt id='645C598F7E'><pre id='645C598F7E'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:explore    Page View:83516
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In